Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.70 Analyst target: $12.17 Upside: 1631.89%
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.